For the quarter ending 2026-03-31, LAB made $21,146K in revenue. $127,068K in net income. Net profit margin of 600.91%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 21,146 | 3,222 | 19,552 | 21,762 |
| Product | 7,706 | -2,404* | 6,728 | 7,608 |
| Services And Other Revenue | 2,132 | 2,936* | 3,340 | 3,526 |
| Total cost of revenue | 9,838 | 532 | 10,068 | 11,134 |
| Gross profit | 11,308 | 2,690 | 9,484 | 10,628 |
| Research and development | 2,117 | 2,081 | 6,356 | 6,222 |
| Selling, general and administrative | 18,607 | 16,454 | 26,595 | 28,105 |
| Restructuring and related charges | 3,080 | 2,075 | 9,428 | 1,727 |
| Transaction and integration expenses | 0 | 724 | 43 | 271 |
| Total operating expenses | 23,804 | 21,334 | 42,422 | 36,325 |
| Interest expense | - | 5 | 10 | 9 |
| Loss from continuing operations | -12,496 | -18,644 | -32,938 | -25,697 |
| Bargain purchase gain | - | - | 0 | 0 |
| Interest income, net | 3,511 | 1,662 | 2,140 | 2,461 |
| Other (expense) income, net | -5,630 | -2,349 | -2,092 | 4,963 |
| Loss from continuing operations before income taxes | -14,615 | -19,336 | -32,900 | -18,282 |
| Income tax (expense) benefit | 11 | -35,900 | -1,216 | -609 |
| Net gain from continuing operations | -14,626 | 7,170* | -31,684 | -17,673 |
| Revenue | - | - | 26,693 | - |
| Cost of revenue | - | - | 14,352 | - |
| Gross profit | - | - | 12,341 | - |
| Selling, general and administrative expenses | - | - | 8,474 | - |
| Research and development | - | - | 4,849 | - |
| Transaction expenses | - | - | 2,203 | - |
| Other (income) expense, net | - | - | -181 | - |
| Total operating expenses | - | - | 15,345 | - |
| Loss from discontinued operations before income taxes | - | - | -3,004 | - |
| Income tax benefit (expense) | - | - | -1 | - |
| Income (gain) from discontinued operations, net of tax | 141,694 | 12,114* | -3,003 | -15,786 |
| Net income (gain) | 127,068 | 19,283 | -34,687 | -33,459 |
| Less induced conversion of redeemable preferred stock | - | 0 | 0 | 0 |
| Net gain attributable to common stockholders | - | 19,283 | -34,687 | -33,459 |
| Basic EPS | 0.33 | 0.05 | -0.09 | -0.09 |
| Diluted EPS | 0.33 | 0.05 | -0.09 | -0.09 |
| Basic Average Shares | 388,202,000 | 385,136,000 | 382,630,000 | 380,498,000 |
| Diluted Average Shares | 388,202,000 | 385,136,000 | 382,630,000 | 380,498,000 |
STANDARD BIOTOOLS INC. (LAB)
STANDARD BIOTOOLS INC. (LAB)